Cancel anytime
Vicarious Surgical Inc. (RBOT)RBOT
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: RBOT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -48.17% | Upturn Advisory Performance 1 | Avg. Invested days: 20 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -48.17% | Avg. Invested days: 20 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.85M USD |
Price to earnings Ratio - | 1Y Target Price 9.5 |
Dividends yield (FY) - | Basic EPS (TTM) -10.17 |
Volume (30-day avg) 19856 | Beta 1.13 |
52 Weeks Range 4.27 - 23.10 | Updated Date 09/18/2024 |
Company Size Small-Cap Stock | Market Capitalization 33.85M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Dividends yield (FY) - | Basic EPS (TTM) -10.17 | Volume (30-day avg) 19856 | Beta 1.13 |
52 Weeks Range 4.27 - 23.10 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.21% | Return on Equity (TTM) -82.71% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value -22396695 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.41 |
Shares Outstanding 5243310 | Shares Floating 3109294 |
Percent Insiders 30.56 | Percent Institutions 35.93 |
Trailing PE - | Forward PE - | Enterprise Value -22396695 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.41 | Shares Outstanding 5243310 | Shares Floating 3109294 |
Percent Insiders 30.56 | Percent Institutions 35.93 |
Analyst Ratings
Rating 3.5 | Target Price 6.5 | Buy - |
Strong Buy 1 | Hold 3 | Sell - |
Strong Sell - |
Rating 3.5 | Target Price 6.5 | Buy - | Strong Buy 1 |
Hold 3 | Sell - | Strong Sell - |
AI Summarization
Vicarious Surgical Inc. (VSUR) Stock Analysis
Company Profile:
Vicarious Surgical Inc. is a medical technology company developing a robotic surgical platform designed to improve surgical outcomes. Their goal is to overcome the limitations of current robotic surgery systems by offering improved dexterity, increased control, and enhanced visualization. The platform consists of three key components: a surgical system with a robotic arm and instruments, an advanced surgical planning system, and an AI-powered control interface.
Top Products and Market Share:
Vicarious Surgical is still in the development stage and has not yet launched its product commercially. Therefore, they do not currently have any products generating revenue or market share.
Financial Performance:
As a pre-revenue company, Vicarious Surgical has not yet generated any revenue or established a track record of financial performance. They are currently focused on research and development activities, which have resulted in significant operating losses.
Growth Trajectory:
Vicarious Surgical has a strong growth potential based on the promising aspects of their surgical platform. The global surgical robotics market is expected to reach $38.2 billion by 2027, and Vicarious Surgical aims to capture a significant portion of this market with its innovative technology.
Market Dynamics:
The surgical robotics market is highly competitive, with established players like Intuitive Surgical (ISRG) holding a dominant market share. However, the market is also experiencing rapid growth, creating opportunities for new entrants like Vicarious Surgical.
Competitors:
- Intuitive Surgical (ISRG): 75% market share
- Stryker (SYK): 5% market share
- Medtronic (MDT): 4% market share
- Johnson & Johnson (JNJ): 3% market share
- Zimmer Biomet (ZBH): 1% market share
Potential Challenges:
- Regulatory approval: Vicarious Surgical needs to obtain regulatory clearance for their surgical platform before commercialization, which can be a lengthy and expensive process.
- Competition: Existing players have a significant head start and established brand recognition in the surgical robotics market.
- Technology risk: Vicarious Surgical's platform relies on novel technologies that may face technical challenges or require further development.
Potential Opportunities:
- Growing market: The surgical robotics market is rapidly growing, providing ample opportunities for new players.
- Technological advancements: AI-powered surgical systems are gaining traction, and Vicarious Surgical's platform leverages AI to enhance surgical outcomes.
- Strategic partnerships: Collaboration with established healthcare institutions or strategic partnerships can facilitate market access.
Fundamental Rating based on AI: 7/10
The AI rating considers various factors such as market size, competition, financial health, and technological advancement. Vicarious Surgical shows promise due to the rapidly growing market, advanced technology, and AI integration. However, their lack of financial performance, regulatory uncertainty, and competition from established players pose significant challenges.
Disclaimer: This information is for informational purposes only and does not constitute financial advice. It is essential to conduct thorough research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vicarious Surgical Inc.
Exchange | NYSE | Headquaters | Waltham, MA, United States |
IPO Launch date | 2020-09-04 | Co-Founder, CEO & Director | Mr. Adam David Sachs |
Sector | Healthcare | Website | https://www.vicarioussurgical.com |
Industry | Medical Devices | Full time employees | 129 |
Headquaters | Waltham, MA, United States | ||
Co-Founder, CEO & Director | Mr. Adam David Sachs | ||
Website | https://www.vicarioussurgical.com | ||
Website | https://www.vicarioussurgical.com | ||
Full time employees | 129 |
Vicarious Surgical Inc. develops and sells single-port surgical robot in the United States. It offers Vicarious Surgical System, a single-port surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.